Based on long-term development strategies and the goal of “win-win,” guided by the principles of mutual trust, complementary advantages, mutual promotion, and joint cooperation, and to further promote the high-quality and efficient transformation of innovative achievements, on April 11, 2024, Shenyang DASAN Pharmaceutical Technology Co., Ltd. and Shanghai Pharmaceuticals (Benxi) North Pharmaceutical Co., Ltd. reached a strategic cooperation agreement, establishing extensive collaboration in the field of chemical drug manufacturing.

Yan Dong, General Manager of Shenyang DASAN, and Li Jianqing, Chairman and General Manager of Shanghai Pharmaceuticals (Benxi) North Pharmaceutical, signed the cooperation agreement on behalf of both companies. Witnesses to the signing included Liu Zhenhao, Vice Chairman of Shenyang DASAN; Kwon Man-ho, Director of the Formulation Research Institute at DASAN Central R&D Center in Korea; Chen Xu, Deputy General Manager of Shenyang DASAN; as well as Lv Xiwei, Party Branch Secretary and Deputy General Manager of Shanghai Pharmaceuticals (Benxi) North Pharmaceutical; Zhang Qiang, Deputy General Manager and Head of Quality; and Ye Xiaohui, Assistant General Manager.

Liu Zhenhao, Vice Chairman of Shenyang DASAN, conveyed the congratulatory message from Mr. Ryu Hyung-sun, Chairman of DASAN Pharmaceutical in Korea: “Currently, the China National Medical Products Administration encourages the advancement of MAH businesses within the same province. Through our previous cooperation, we have gained a deep understanding of Shanghai Pharmaceuticals (Benxi) North Pharmaceutical’s advanced production facilities and extensive manufacturing experience. There is no doubt that Shanghai Pharmaceuticals (Benxi) North Pharmaceutical is a strong partner for Shenyang DASAN. We hope that this strategic cooperation will serve as the starting point for continued collaboration in the future.”

Li Jianqing, Chairman and General Manager of Shanghai Pharmaceuticals (Benxi) North Pharmaceutical, stated: “We will build upon our existing collaboration with DASAN Pharmaceutical and embark on a new chapter of cooperation, which will include cooperation across a wider range of dosage forms. North Pharmaceutical will certainly uphold the principles of integrity, cooperation, and win-win outcomes, vigorously developing our technological capabilities and enhancing independent innovation. Let us join hands and work together to create a brilliant future.”

Shanghai Pharmaceuticals (Benxi) North Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (a Fortune Global 500 company), was established in November 2014. Its objective is to build a domestic leading, internationally aligned industrial base for the full chemical drug industry chain, encompassing R&D, pilot-scale, and industrialization; a pilot platform for biopharmaceutical antibody R&D; and an ADC drug manufacturing base, ultimately creating a world-class innovative drug and advanced formulation MAH manufacturing hub with core competitiveness. Through years of development, the company has acquired diversified platforms, high-tech talent, an excellent management team, and top-tier hardware facilities, enabling it to provide comprehensive services and full-spectrum cooperation across the entire pharmaceutical value chain, from drug development to market launch.

Shenyang DASAN Pharmaceutical Technology Co., Ltd., established in July 2014, became a Sino-Korean joint venture in August 2020 after introducing strategic investment from DASAN Pharmaceutical in Korea. Shenyang DASAN is a high-tech enterprise primarily focused on the research and development of novel drug delivery systems (DDS), dedicated to transforming DDS technologies into industrial applications. In partnership with Dasan Pharmaceutical, a Korean company specializing in advanced drug delivery technology research and production, Shenyang DASAN has invested over RMB 10 million to establish technology development platforms for taste-masking, poorly soluble drug microencapsulation, and sustained/controlled-release pellets.